Compare TGTX & CAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | CAG |
|---|---|---|
| Founded | 1993 | 1919 |
| Country | United States | United States |
| Employees | N/A | 26100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.9B |
| IPO Year | 2008 | 1994 |
| Metric | TGTX | CAG |
|---|---|---|
| Price | $49.93 | $14.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 17 |
| Target Price | ★ $49.80 | $16.88 |
| AVG Volume (30 Days) | 2.3M | ★ 13.1M |
| Earning Date | 05-04-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 9.84% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $2,785,000.00 | ★ $1,500,000,000.00 |
| Revenue This Year | $49.08 | N/A |
| Revenue Next Year | $26.69 | N/A |
| P/E Ratio | $293.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.76 | $12.53 |
| 52 Week High | $59.30 | $20.32 |
| Indicator | TGTX | CAG |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 51.80 |
| Support Level | $45.37 | $13.47 |
| Resistance Level | $58.08 | $15.89 |
| Average True Range (ATR) | 2.12 | 0.38 |
| MACD | -0.51 | -0.06 |
| Stochastic Oscillator | 38.04 | 24.60 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.